RBC Capital analyst Sean Dodge raised the firm's price target on Teladoc to $140 from $110 and keeps an Outperform rating on the shares. The analyst says the company's Q4 results exceeded expectations on all metrics while its 2020 revenue guidance implies 27% growth at the midpoint, which is above the Street mean of 24%-25%. Dodge remains positive on Teladoc's "new member adds, cross-selling, and rapidly increasing visits and utilization".

Reports Q1 revenue $646.13M, consensus $637.29M. "We are pleased to report a solid start to the year, with strength in both revenue and adjusted EBITDA in the first quarter," said Mala Murthy, acting chief executive officer and chief financial officer of Teladoc Health. "During this period of transition, our team remains laser focused on our key initiatives, which include building upon our market leadership position; driving increased product penetration through our large installed base of over 90 million virtual care members; and accelerating our bottom-line performance."